Neuroprotective effects of hydrated fullerene C60: Cortical and hippocampal EEG interplay in an amyloid-infused rat model of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 45, Issue 1, 2015, Pages 217-233

  Vorobyov, Vasily ^a   Kaptsov, Vladimir ^a   Gordon, Rita ^a   Makarova, Ekaterina ^b   Podolski, Igor ^b   Sengpiel, Frank ^c  

^a INSTITUTE OF CELL BIOPHYSICS   (Russian Federation)

^b INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Amyloid ; brain oscillation; dopamine agonist; neurodegenerative disorder; neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOMORPHINE; FULLERENE; HYDRATED FULLERENE C 60; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); DOPAMINE RECEPTOR STIMULATING AGENT; FULLERENE C60; FULLERENE DERIVATIVE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BETA RHYTHM; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; FRONTAL CORTEX; HIPPOCAMPAL CA1 REGION; INTRAHIPPOCAMPAL DRUG ADMINISTRATION; MALE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; THETA RHYTHM; YAWNING; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CORTEX; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ELECTRODE IMPLANT; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; FULLERENES; HIPPOCAMPUS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84924108189     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142469     Document Type: Article

References (68)

1. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
2. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52, 3-13.
3. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
4. German DC, Eisch AJ (2004) Mouse models of Alzheimer's disease: Insight into treatment. Rev Neurosci 15, 353-369.
5. Turner PR, rsquo O, Connor K, TateWP, AbrahamWC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70, 1-32.
6. Goutagny R, Gu N, Cavanagh C, Jackson J, Chabot JG, Quirion JG, Krantic S, Williams S (2013) Alterations in hippocampal network oscillations and theta-gamma coupling arise before Aβ overproduction in a mouse model of Alzheimer's disease. Eur J Neurosci 37, 1896-1902.
7. Dong S, Duan Y, Hu Y, Zhao Z (2012) Advances in the pathogenesis of Alzheimer's disease: A re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 1, 18.
8. Bobkova NV, Garbuz DG, Nesterova I, Medvinskaya N, Samokhin A, Alexandrova I, Yashin V, Karpov V, Kukharsky MS, Ninkina NN, Smirnov AA, Nudler E, Evgen'evM (2014) Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer's disease. J Alzheimers Dis 38, 425-435.
9. Devi L, Ohno M (2010) Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Eur J Neurosci 31, 110-118.
10. Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL (2013) Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. J Alzheimers Dis 33, 1041-1049.
11. Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL (2013) Chronic administration of Dimebon does not ameliorate amyloid-&brta; pathology in 5xFAD transgenic mice. J Alzheimers Dis 36, 589-596.
12. McLarnon JG, Ryu JK (2008) Relevance of Abeta1-42 intrahippocampal injection as an animal model of inflamed Alzheimer's disease brain. Curr Alzheimer Res 5, 475-480.
13. O'Hare E, Scopes DI, Treherne JM, Monaghan J, Palmer PM, Amijee H, Kim EM (2011) Novel anti-inflammatory compound SEN1176 alleviates behavioral deficits induced following bilateral intrahippocampal injection of aggregated amyloid-&brta;1-42. J Alzheimers Dis 25, 219-229.
14. Babiloni C, Vecchio F, Lizio R, Ferri R, Rodriguez G, Marzano N, Frisoni GB, Rossini PM (2011) Resting state cortical rhythms in mild cognitive impairment and Alzheimer's disease: Electroencephalographic evidence. J Alzheimers Dis 26 (Suppl 3), 201-214.
15. Delbeuck X, Van Der Linden M, Collette F (2003) Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev 13, 79-92.
16. Jeong J (2004) EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol 115, 1490-1505.
17. Wang J, Ikonen S, Gurevicius K, Groen T, Tanila H (2002) Alteration of cortical EEG in mice carrying mutated human APP transgene. Brain Res 943, 181-190.
18. Sánchez-Alavez M, Chan SL, Mattson MP, Criado JR (2007) Electrophysiological and cerebrovascular effects of the alphasecretase-derived form of amyloid precursor protein in young and middleaged rats. Brain Res 1131, 112-117.
19. Mugantseva EA, Podolski IY (2009) Animal model of Alzheimer's disease: Characteristics of EEG and memory. Cent Eur J Biol 4, 507-514.
20. Satoh M, Takayanagi I (2006) Pharmacological studies on fullerene (C60), a novel carbon allotrope, and its derivatives. J Pharmacol Sci 100, 513-518.
21. Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, Wang Q (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 97, 1-13.
22. Cheng B, Gong H, Xiao H, Petersen RB, Zheng L, Huang K (2013) Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases. Biochim Biophys Acta 1830, 4860-4871.
23. Andrievsky GV, Bruskov VI, Tykhomyrov AA, Gudkov SV (2009) Peculiarities of the antioxidant and radioprotective effects of hydrated C60 fullerene nanostuctures in vitro and in vivo. Free Radic Biol Med 47, 786-793.
24. Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain.Areview. Free Radic Res 36, 1307-1313.
25. Podolski IY, Podlubnaya ZA, Kosenko EA, Mugantseva EA, Makarova EG, Marsagishvili LG, Shpagina MD, Kaminsky YG, AndrievskyGV, KlochkovVK (2007) Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J Nanosci Nanotechnol 7, 1479-1485.
26. Podolski IY, Podlubnaya ZA, GodukhinOV (2010) Fullerenes C60, antiamyloid action, the brain, and cognitive processes. Biophysics 55, 71-76 (in Russian).
27. Li C, Mezzenga R (2013) The interplay between carbon nanomaterials and amyloid fibrils in bio-nanotechnology. Nanoscale 5, 6207-6218.
28. Makarova EG, Gordon RY, Podolski IY (2012) Fullerene C60 prevents neurotoxicity induced by intrahippocampal microinjection of amyloid-beta peptide. J Nanosci Nanotechnol 12, 119-126.
29. Ward LM (2003) Synchronous neural oscillations and cognitive processes. Trends Cogn Sci 7, 553-559.
30. Bobkova N, Vorobyov V, Medvinskaya N, Aleksandrova I, Nesterova I (2008) Interhemispheric EEG differences in olfactory bulbectomized rats with different cognitive abilities and brain beta-amyloid levels. Brain Res 1232, 185-194.
31. Vorobyov V, Sengpiel F (2008) Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats. Exp Brain Res 191, 277-287.
32. Carlsson A, KehrW, LindqvistM (1977) Agonist-antagonist interaction on dopamine receptors in brain, as reflected in the rates of tyrosine and tryptophan hydroxylation. J Neural Transm 40, 99-113.
33. Poewe W, Wenning GK (2000) Apomorphine: An underutilized therapy for Parkinson's disease. Mov Disord 15, 789-794.
34. Koch G, Esposito Z, Codec, agrave C, Mori F, Kusayanagi H, Monteleone F, Di Lorenzo F, Bernardi G, Martorana A (2011) Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. Clin Neurophysiol 122, 703-707.
35. Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, Motomura K, Soejima N, Yamasaki R, Hashimoto T, Tabira T, LaFerla FM, Kira J (2011) Apomorphine treatment in Alzheimer mice promoting amyloid-&brta; degradation. Ann Neurol 69, 248-256.
36. Ribari?c S (2012) The pharmacological properties and therapeutic use of apomorphine. Molecules 17, 5289-5309.
37. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A Stereotaxic Atlas of the Rat Brain, Plenum Press, New York.
38. Garai K, Frieden C (2013) Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ. Proc Natl Acad Sci U S A 110, 3321-3326.
39. Gray CM, Engel AK, Koenig P, Singer W (1992) Synchronization of oscillatory neuronal responses in cat striate cortex: Temporal properties. Vis Neurosci 8, 337-347.
40. Gal'chenko AA, Vorobyov VV (1999) Analysis of electroencephalograms using a modified amplitude-interval algorithm. Neurosci Behav Physiology 29, 157-160.
41. Stigsby B, Obrist WD, Sulg IA (1973) Automatic data acquisition and period-amplitude analysis of the electroencephalogram. Comput Programs Biomed 3, 93-104.
42. VorobyovV, KaptsovV, KovalevG, Sengpiel F (2011) Effects of nootropics on the EEG in conscious rats and their modification by glutamatergic inhibitors. Brain Res Bull 85, 123-132.
43. Nie J, Luo Y, Huang XN, Gong QH, Wu Q, Shi JS (2010) Icariin inhibits beta-amyloid peptide segment 25-35 induced expression of beta-secretase in rat hippocampus. Eur J Pharmacol 626, 213-218.
44. Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS (2003) The toxicity in vitro of beta-amyloid protein. Biochem J 311 (Pt 1), 1-16.
45. Frozza RL, Horn AP, Hoppe JB, Sim, atilde, o F, Gerhardt D, Comiran RA, Salbego CG (2009) A comparative study of beta-amyloid peptides Abeta1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures. Neurochem Res 34, 295-303.
46. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA (2003) The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 23, 5531-5535.
47. Nobili L, De Gennaro L, Proserpio P, Moroni F, Sarasso S, Pigorini A, De Carli F, Ferrara M (2012) Local aspects of sleep: Observations from intracerebral recordings in humans. Prog Brain Res 199, 219-232.
48. Fell J, Axmacher N (2011) The role of phase synchronization in memory processes. Nat Rev Neurosci 12, 105-118.
49. Inostroza M, Born J (2013) Sleep for preserving and transforming episodic memory. Ann Rev Neurosci 36, 79-102.
50. Rauchs G, Schabus M, Parapatics S, Bertran F, Clochon P, Hot P, Denise P, Desgranges B, Eustache F, Gruber G, Anderer P (2008) Is there a link between sleep changes and memory in Alzheimer's disease? Neuroreport 19, 1159-1162.
51. Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, Shen CK, Luh TY, Choi DW, Lin TS (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci U S A 94, 9434-9439.
52. Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O'Malley KL (2001) Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 7, 243-246.
53. Kordonets OL, Godukhin OV, Podolski IYa (2008) Effect of fullerenes C60 on the activity of pyramidal neurons in the CA1 field of rat hippocampal slices. Dokl Biol Sci 423, 1-3 (in Russian).
54. Bland BH, Oddie SD (2001) Theta band oscillation and synchrony in the hippocampal formation and associated structures: The case for its role in sensorimotor integration. Behav Brain Res 127, 119-136.
55. Lisman JE, Jensen O (2013) The aβ ? aβ neural code. Neuron 77, 1002-1016.
56. O'Keefe J (1993) Hippocampus, theta, and spatial memory. Curr Opin Neurobiol 3, 917-924.
57. Quick KL, Ali SS, Arch R, Xiong C, Wozniak D, Dugan LL (2008) A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol Aging 29, 117-128.
58. Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109, 411-420.
59. Bagetta G, De Sarro G, Priolo E, Nistic, ograve G (1988) Ventral tegmental area: Site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats. Br J Pharmacol 95, 860-866.
60. Sebban C, ZhangXQ, Tesolin-Decros B, Millan MJ, Spedding M (1999) Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br J Pharmacol 128, 1045-1054.
61. Lee M (2013) Neurotransmitters and microglial-mediated neuroinflammation. Curr Protein Pept Sci 14, 21-32.
62. McCormick AV, Wheeler JM, Guthrie CR, Liachko NF, Kraemer BC (2013) Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry 73, 464-471.
63. Martorana A, Di Lorenzo F, Esposito Z, Lo Giudice T, Bernardi G, Caltagirone C, Koch G (2013) Dopamine D--2-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology 64, 108-113.
64. Wisman LA, Sahin G, Maingay M, Leanza G, Kirik D (2008) Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. J Neurosci 28, 7797-7807.
65. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303, 791-804.
66. Li C, Zhao R, Gao K, Wei Z, YinMY, Lau LT, Chui D, Hoi Yu AC (2011) Astrocytes: Implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res 8, 67-80.
67. Yang X, Ebrahimi A, Li J, Cui Q (2014) Fullerenebiomolecule conjugates and their biomedicinal applications. Int J Nanomedicine 9, 77-92.
68. Ubhi K, Masliah E (2013) Alzheimer's disease: Recent advances and future perspectives. J Alzheimers Dis 33 (Suppl. 1), 185-194.